Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

What this study is about

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.

Who can join (things the study team will check)

✅ You may be able to join if…

• Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
• In the investigator's assessment, the participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of > 6 months.
• Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
• Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
• Participants must have adequate organ function.
• Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
• Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.

🚫 You may not be able to join if…

• Participant has melanoma of uveal/ocular origin.
• Participant has symptomatic untreated brain metastases.
• Participant received more than 1 prior line of therapy.
• Participant received prior therapy for metastatic disease
• Participants with a BRAF V600 mutation-positive tumor received prior adjuvant/neoadjuvant ICI therapy only
• Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
• Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
• Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated >1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
• Participant has a history of allogeneic cell or organ transplant. Other protocol defined inclusion/exclusion criteria could apply.

Where this trial is running

• University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
• City of Hope, Duarte, California, United States
• USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
• California Pacific Medical Center, San Francisco, California, United States
• University of Colorado Cancer Center, Aurora, Colorado, United States
• Orlando Health Cancer Institute, Orlando, Florida, United States
• University of Illinois Hospital & Health Sciences System, Chicago, Illinois, United States
• University of Kansas, Kansas City, Kansas, United States
• University of Louisville - James Graham Brown Cancer Center, Louisville, Kentucky, United States
• National Cancer Institute, Bethesda, Maryland, United States
• Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan, United States
• Henry Ford Health, Detroit, Michigan, United States

+ 69 more sites.

Who to contact

Iovance Biotherapeutics https://www.tilvance-301.com · 1-844-845-4682 · Clinical.Inquiries@iovance.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05727904.